FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079483713> ?p ?o ?g. }

• W2079483713 endingPage "e98929" @default.
• W2079483713 startingPage "e98929" @default.
• W2079483713 abstract "Emergent resistance can be progressive and driven by global signaling aberrations. All-trans retinoic acid (RA) is the standard therapeutic agent for acute promyelocytic leukemia, but 10–20% of patients are not responsive, and initially responsive patients relapse and develop retinoic acid resistance. The patient-derived, lineage-bipotent acute myeloblastic leukemia (FAB M2) HL-60 cell line is a potent tool for characterizing differentiation-induction therapy responsiveness and resistance in t(15;17)-negative cells. Wild-type (WT) HL-60 cells undergo RA-induced granulocytic differentiation, or monocytic differentiation in response to 1,25-dihydroxyvitamin D3 (D3). Two sequentially emergent RA-resistant HL-60 cell lines, R38+ and R38-, distinguishable by RA-inducible CD38 expression, do not arrest in G1/G0 and fail to upregulate CD11b and the myeloid-associated signaling factors Vav1, c-Cbl, Lyn, Fgr, and c-Raf after RA treatment. Here, we show that the R38+ and R38- HL-60 cell lines display a progressive reduced response to D3-induced differentiation therapy. Exploiting the biphasic dynamic of induced HL-60 differentiation, we examined if resistance-related defects occurred during the first 24 h (the early or “precommitment” phase) or subsequently (the late or “lineage-commitment” phase). HL-60 were treated with RA or D3 for 24 h, washed and retreated with either the same, different, or no differentiation agent. Using flow cytometry, D3 was able to induce CD38, CD11b and CD14 expression, and G1/G0 arrest when present during the lineage-commitment stage in R38+ cells, and to a lesser degree in R38- cells. Clustering analysis of cytometry and quantified Western blot data indicated that WT, R38+ and R38- HL-60 cells exhibited decreasing correlation between phenotypic markers and signaling factor expression. Thus differentiation induction therapy resistance can develop in stages, with initial partial RA resistance and moderate vitamin D3 responsiveness (unilineage maturation block), followed by bilineage maturation block and progressive signaling defects, notably the reduced expression of Vav1, Fgr, and c-Raf." @default.
• W2079483713 created "2016-06-24" @default.
• W2079483713 creator A5002294450 @default.
• W2079483713 creator A5003161155 @default.
• W2079483713 creator A5027126263 @default.
• W2079483713 creator A5027960117 @default.
• W2079483713 creator A5032707584 @default.
• W2079483713 creator A5032779286 @default.
• W2079483713 date "2014-06-12" @default.
• W2079483713 modified "2023-10-14" @default.
• W2079483713 title "Retinoic Acid Therapy Resistance Progresses from Unilineage to Bilineage in HL-60 Leukemic Blasts" @default.
• W2079483713 cites W1512182914 @default.
• W2079483713 cites W1542216061 @default.
• W2079483713 cites W1752169014 @default.
• W2079483713 cites W1766658148 @default.
• W2079483713 cites W1835484652 @default.
• W2079483713 cites W1955568895 @default.
• W2079483713 cites W1967585026 @default.
• W2079483713 cites W1972602773 @default.
• W2079483713 cites W1978961590 @default.
• W2079483713 cites W1980481628 @default.
• W2079483713 cites W1983971021 @default.
• W2079483713 cites W1984013377 @default.
• W2079483713 cites W1995083340 @default.
• W2079483713 cites W1998209690 @default.
• W2079483713 cites W2002393876 @default.
• W2079483713 cites W2013554303 @default.
• W2079483713 cites W2020809426 @default.
• W2079483713 cites W2020868655 @default.
• W2079483713 cites W2022177704 @default.
• W2079483713 cites W2022360690 @default.
• W2079483713 cites W2027044879 @default.
• W2079483713 cites W2028349946 @default.
• W2079483713 cites W2029804363 @default.
• W2079483713 cites W2030193231 @default.
• W2079483713 cites W2040347441 @default.
• W2079483713 cites W2044596216 @default.
• W2079483713 cites W2053153929 @default.
• W2079483713 cites W2056319477 @default.
• W2079483713 cites W2062114671 @default.
• W2079483713 cites W2062558830 @default.
• W2079483713 cites W2064587001 @default.
• W2079483713 cites W2072219641 @default.
• W2079483713 cites W2077333588 @default.
• W2079483713 cites W2087133148 @default.
• W2079483713 cites W2091216334 @default.
• W2079483713 cites W2093481931 @default.
• W2079483713 cites W2097298305 @default.
• W2079483713 cites W2098726019 @default.
• W2079483713 cites W2108042825 @default.
• W2079483713 cites W2127819454 @default.
• W2079483713 cites W2142945689 @default.
• W2079483713 cites W2150926065 @default.
• W2079483713 cites W2159159025 @default.
• W2079483713 cites W2169987792 @default.
• W2079483713 cites W2172677241 @default.
• W2079483713 cites W2307142846 @default.
• W2079483713 cites W2333011916 @default.
• W2079483713 cites W2343463909 @default.
• W2079483713 cites W2399204786 @default.
• W2079483713 cites W248352688 @default.
• W2079483713 cites W4234909704 @default.
• W2079483713 doi "https://doi.org/10.1371/journal.pone.0098929" @default.
• W2079483713 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4055670" @default.
• W2079483713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24922062" @default.
• W2079483713 hasPublicationYear "2014" @default.
• W2079483713 type Work @default.
• W2079483713 sameAs 2079483713 @default.
• W2079483713 citedByCount "13" @default.
• W2079483713 countsByYear W20794837132015 @default.
• W2079483713 countsByYear W20794837132017 @default.
• W2079483713 countsByYear W20794837132018 @default.
• W2079483713 countsByYear W20794837132020 @default.
• W2079483713 countsByYear W20794837132021 @default.
• W2079483713 countsByYear W20794837132022 @default.
• W2079483713 crossrefType "journal-article" @default.
• W2079483713 hasAuthorship W2079483713A5002294450 @default.
• W2079483713 hasAuthorship W2079483713A5003161155 @default.
• W2079483713 hasAuthorship W2079483713A5027126263 @default.
• W2079483713 hasAuthorship W2079483713A5027960117 @default.
• W2079483713 hasAuthorship W2079483713A5032707584 @default.
• W2079483713 hasAuthorship W2079483713A5032779286 @default.
• W2079483713 hasBestOaLocation W20794837131 @default.
• W2079483713 hasConcept C10205521 @default.
• W2079483713 hasConcept C104317684 @default.
• W2079483713 hasConcept C148738053 @default.
• W2079483713 hasConcept C159912055 @default.
• W2079483713 hasConcept C171779818 @default.
• W2079483713 hasConcept C185592680 @default.
• W2079483713 hasConcept C203014093 @default.
• W2079483713 hasConcept C2776601000 @default.
• W2079483713 hasConcept C2778513237 @default.
• W2079483713 hasConcept C2779282312 @default.
• W2079483713 hasConcept C2779963572 @default.
• W2079483713 hasConcept C2779982571 @default.
• W2079483713 hasConcept C2781121885 @default.
• W2079483713 hasConcept C28328180 @default.
• W2079483713 hasConcept C502942594 @default.

• next